Fundamental Analysis of Sun Pharmaceutical Industries Ltd. - Growth / Value Index



SUNPHARMA - Valuation Highlights

Valuation Analysis

   Tremendous increasing in Book Value last 3 year
   Tsr Value Index - Poor Score of 23.61
   Price to Book Ratio of 5.71 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ Screener/ About
Price to Earning 38.59 38.04 -6.34 %    
Price to Book 5.71 5.78 -5.46 % 2.74    
Price to Sales 7.45 7.93 -1.08 %    
Enterprise Value to EBITDA Multiple 24.69 -10.12 %    


SUNPHARMA - Profitability Highlights

Profitability Analysis

   Piotroski F Score - Excellent Value of 8.0
   Tremendous increasing trend in Net Profit for last 3 year
   Company Earning excess return
   All key Trailing Twelve Months Margin growing by 15 %
   EBITDA is continuously increasing for last 3 Years
   Steady ROE in range of 15 to 20 for last 3 years
   Steady ROA in range of 8 to 12 for last 3 years
   Good Return On Capital Employed of 14.82
   Good Return on Equity of 14.98% is achieved by the company
   Good Net Margin of 19.29% is achieved by the company
   Very Low Dividend Yield of 0 %
   Low Earning Yield of 2.59 %
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ Screener/ About
Return On Equity 14.98 15.18 0.940 % 3.14    
Return On Asset 11.64 11.91 6.25 % 2.47    
Net Profit Margin 19.29 20.85 5.61 % 16.45    
Operating Profit Margin 64.93 23.71 12.41 % 29.40    
EBITDA Margin 30.37 31.49 10.02 % 28.33    


Highlights
Market Cap4009.05 B
Enterprise Value3926.43 B
Price/Book TTM5.71
Outstanding Share2399.33 M
Float/ Outstanding Share44.39%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No3.09
Peter Lynch Ratio0.370
Piotroski F Score8.00                  
Altman Z Score14.56                  
Sloan Ratio0.0239
Peter Lynch Fair Value761.63


SUNPHARMA - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 53777.09 (Cr) 8.42 % 6.89 %
Gross Profit 39339.68 (Cr) 59.75 % 7.79 %
EBITDA 16331.46 (Cr) 19.27 % 0.920 %
Net Profit 10376.10 (Cr) 14.50 % 5.79 %
EPS 43.30 14.29 % NA


SUNPHARMA - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 93.75
   Altman Z Score of 14.56 suggests good Stability
   Decreasing debt with Increasing revenue
   Company financial liquidity has improved
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ Screener/ About
Debt to Equity Ratio 0.0278 -40.47 % 0.0277    
Cash Ratio 0.623 -44.63 %    
Quick Ratio 2.33 17.72 % 2.33    
Shareholders Equity 78.41 5.26 %    
Debt to EBITDA 0.121 -43.39 %    


Historical Valuation Ratios of Sun Pharmaceutical Industries Ltd.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Sun Pharmaceutical Industries Ltd.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Sun Pharmaceutical Industries Ltd.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Sun Pharmaceutical Industries Ltd.

Historical Solvency Ratios
Loading ...
Quick Overview of Fundamental Filters